Company: Olympus Corporation Representative Director, President and CEO: Hiroyuki Sasa (Code: 7733, First Section, Tokyo Stock Exchange) Contact: Tetsuo Hyakutake, General Manager, Public Relations and IR Office

Olympus to Construct New Facilities at Three Major Medical Production Bases

Olympus Corporation announced today plans to construct new facilities at the company's major medical-related production bases in the Aizu, Shirakawa and Aomori areas, aiming to enhance capacity, improve efficiency and strengthen business continuity planning. The additional facilities are expected to further stabilize production of medical products, which are positioned as a core business in the company medium-term business plan.

Production bases and planned construction

| Production bases | Investment (Approx.) | Site area | New floor space |
|---|-------------------------|-----------------------|-----------------------|
| Aizu 500 Aza-Muranishi, Oaza-Niidera, Monden-machi, Aizu-Wakamatsu-shi, Fukushima Prefecture Core business: Development and production of scopes and peripherals for medical endoscopes | 9.4 billion yen | 83,029 m ² | 22,135 m ² |
| Shirakawa 3-1 Aza-Ohkamiyama, Oaza-Odakura, Nishigo-mura, Nishi-Shirakawa-gun, Fukushima Prefecture Core business: Development, production and purchase of medical endoscope chassis | 8.6 billion yen | 76,220 m ² | 23,900 m ² |
| Aomori 248-1 Okkonoki 2-chome, Kuroishi-shi, Aomori Prefecture Core business: Development and production of instruments for medical treatments | 1.7 billion yen | 39,471 m ² | 3,000 m ² |
| Total | 19.7 billion yen | | |

The buildings will be constructed on existing premises, so additional land will not be acquired. As a result of the board of directors passing a resolution to approve the construction plan today, new construction will be carried under a schedule targeting completion by the end of fiscal 2016.

Depreciation and other expenses related to these new fixed assets will accrue in the future, but are expected to have minimal impact on the company's financial results in the current fiscal year.

Reference: Consolidated Financial Forecasts for Current Fiscal Year (announced on November 12, 2012) and Consolidated Financial Results for Previous Fiscal Year

| | Consolidated | Consolidated | | | |
|--|--------------|------------------|-----------------|------------|--|
| | net sales | operating income | ordinary income | net income | |
| Consolidated financial forecasts for fiscal year ending March 2013 | 757,000 | 38,000 | 16,000 | 8,000 | |
| Consolidated financial results for fiscal year ended March 2012 | 848,548 | 35,518 | 17,865 | -48,985 | |